“ORAL COMMUNICATION | Semaglutide Plus Empagliflozin Improves Renal Outcomes Compared With Monotherapies in Type 2 Diabetes: A Real-World Study”. Italian Journal of Medicine, vol. 20, no. s1, May 2026, https://doi.org/10.4081/.